allergic asthma allergic rhinitis gene expression analysis microarray allergisch astma allergisch rinitis gen expressie analyse microarray
Conditions
Interventions
2. Spirometry
3. Mathacholine challenge
4. Skin-prick test
5. Nasal allergen provocation (nonatopic and healthy subjects only)
6. 4 nasal biopsies
7. Bronchoscopy with 4 brushes and 2 biopsies.
Sponsors
Academisch Medisch Centrum, Amsterdam
Eligibility
Inclusion criteria
Inclusion criteria: Asthmatics: 1. Age 18-50 years; 2. History of episodic chest tightness and wheezing; 3. Intermittent or mild persistent asthma according to the criteria by the Global Initiative for Asthma; 4. Non-smoking or stopped smoking more than 12 months ago and 5 pack years or less; 5. Clinically stable, no exacerbations within the last 6 weeks prior to the study. Occasional usage of inhaled short-acting β2-agonists as rescue medication is allowed, prior and during the study; 6. Steroid-naïve or those patients who are currently not on corticosteroids and have not taken any corticosteroids by any dosing-routes within 8 weeks prior to the study; 7. Baseline FEV1 ≥ 70% of predicted; 8. Airway hyperresponsiveness, indicated by a positive methacholine challenge with PC20 8 mg/ml; 8. Negative history of pulmonary and any other relevant disease.
Exclusion criteria
Exclusion criteria: 1. History of clinical significant hypotensive episodes or symptoms of fainting, dizziness, or light-headedness; 2. Chronic use of any other medication for treatment of lung disease other than short-acting β2-agonists during the study; 3. Ongoing use of tobacco products of any kind or previous usage with a total pack year ≥ 6.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| mRNA expression profiles of upper and lower airway epithelium. | — |
Contacts
Public ContactA.H. Wagener
Meibergdreef 9
Outcome results
None listed